Polio Vaccines Market: Moving Towards a Brighter Future 2018-2026

Polio Vaccines Market: Moving Towards a Brighter
Future 2018-2026
Polio Vaccines Market - Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2018-2026
Poliomyelitis is highly infectious disease caused by poliovirus. It is also known as polio or infantile
paralysis. The virus belongs to genus Enterovirus which is a type of single-stranded RNA virus. There
are three serotypes of poliovirus: P1, P2 and P3 and development of immunity to one serotype does not
produce significant immunity to the other serotypes. The virus is transmitted primarily via the fecaloral route, by ingesting contaminated food or water and less commonly through oral-oral route. Those
who are infected may spread the disease for up to 6 weeks even if no symptoms are present. Poliovirus
colonizes the gastrointestinal tract, specifically intestine and oropharynx and after about a week, it
invades local lymphoid tissue and enters bloodstream, and then may infect cells of the central nervous
system. Replication of poliovirus in motor neurons of the anterior horn and brain stem results in
destruction of cell and thus causes the typical manifestations of poliomyelitis. This is projected to favor
a significant growth for polio vaccines market over the forecast period. Click To Read More On Polio
Vaccines Market.
Symptoms of Poliomyelitis:
Polio mainly affects children under 5 years of age. Up to 70% of all the infections in children are
without any symptoms and about 25-30% of infections in children causes’ nonspecific illness without
clinical or laboratory evidence of central nervous system invasion. This has created a gesture for the
organizations to focus on the vaccines options for making prophylactic approach towards the
prevention of the disorder, which in turn is expected to fuel the polio vaccines market in the near
future.
Polio vaccines market relies on the fact that around 1% of polio cases can develop into paralytic polio
which causes paralysis in the spinal cord (spinal polio), brainstem (bulbar polio), or both (bulbospinal
polio).According to WHO, 1 in 200 infections leads to irreversible paralysis. Among those paralyzed,
5% to 10% die when their breathing muscles become immobilized. The statistics regarding the
prevalence of the disorder is expected to be one of the crucial factor that is to fuel the market of polio
vaccines.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/380
In a report, WHO has reported that Polio cases have decreased by over 99% since 1988, from an
estimated 350 000 cases then, to 74 reported cases in 2015. The reduction is the result of the global
effort to eradicate the disease. Of the 3 serotypes, P2 was eradicated in 1999 and number of cases of P3
has decreased significantly.
Sanofi Pasteur and Bilthoven Biologicals/ Serum Institute of India are the 2 companies which was
awarded in 2014 by UNICEF for the supply of IPV in 1, 5 and 10 dose vials, and long term supply
agreements were established through to 2018.
Since 2000, UNICEF OPV procurement has averaged 1.8 Bn doses annually. GPEI launched the “End
Game Strategic Plan 2013-2018” at the World Health Assembly in May 2013. This comprehensive
strategy focuses on eliminating both wild and vaccine-derived polio incidence through routine
immunization programs thereby gradually replacing OPV use with IPV vaccine. This in turn is
expected to favour the growth in polio vaccines industry in the near future.
According to UNICEF report, Bio Farma (Indonesia), GlaxoSmithKline (GSK) (UK) and Sanofi
Pasteur (France) are the only OPV bulk manufacturers. Novartis (Switzerland) has stopped their
manufacture of OPV.
Other players of polio vaccine market are: Merck & Co, Bibcol, Pfizer, Beijing Tiantan Biological,
Bio-Med, Panacea Biotec Ltd, Adithya Vaccine Pharma, Sinovac Biotech Ltd, IPOLand Aventis
Pasteur.
America has been declared polio free in 1994. In 2004, polio was declared to be eliminated from
Australia, China and other 37 Pacific countries. Since 2011, there has been no cases of wild polio
infections in India. This factor is projected to hinder the polio vaccines market in the near future.
There are only 3 countries left in which wild polio infections still persist; Afghanistan, Nigeria, and
Pakistan, which are somehow the reason for significant growth in the polio vaccines market in the near
future.
Indigenous wild poliovirus type 2 has not been detected since 1999. In 2015, the World Health
Assembly agreed that all Member States which currently use OPV should prepare for the global
withdrawal of the type 2 component of OPV in April 2016. According to WHO, member countries are
required to introduce at least 1 dose of the IPV into routine immunization schedule.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Poliomyelitis is highly infectious disease caused by poliovirus. It is also known as polio or infantile paralysis. The virus belongs to genus Enterovirus which is a type of single-stranded RNA virus. There are three serotypes of poliovirus: P1, P2 and P3 and development of immunity to one serotype does not produce significant immunity to the other serotypes.

Download Report